Gene Therapy Reduces LDL by 62% in High-Risk Patients
Experimental therapy VERVE-102, developed by Eli Lilly and Verve Therapeutics, uses base-editing to deactivate PCSK9 gene.
One-time IV treatment for high-risk patients, with effects lasting up to 18 months in some participants.
Phase 1b trial with 35 adults showed treatment was generally well-tolerated.
Experts caution that larger, long-term trials are needed for safety verification.
20 hours ago